In a recent McKinsey study, the Indian pharmaceuticals market is projected to grow to USD 55 billion by 2020, a level comparable to all developed markets other than the US, Japan and China. India's biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30% a year to reach US$ 100 billion by 2025.
While the pharmaceutical industry’s performance since 2010 has been impressive, it is also facing a period of significant structural shifts. The broader healthcare sector is experiencing discontinuous developments. Manifold rise in public healthcare spending, rising patient awareness, expanding insurance coverage across the income pyramid and the emergence of new hospital formats are exacerbating these shifts. In recent past, industry structure in pharmaceuticals has changed with significant changes in the leader board (four of the top ten players, including the market leader, are new entrants). Over the past 5 years, the distinction between local players and multinational companies has increasingly blurred. Traditional sources of growth are making room for newer ones in patented products, consumer healthcare drugs, biologics, vaccines, and the public health market.
As part of this evolution, there is a need in pharmaceutical organizations to re-define existing practices, introduce new technology and models, and cultivate a performance-driven culture that delivers improved quality of access, care and solutions.
The Global Executive MBA Degree in Pharmaceutical Management is a programme designed to prepare for this transformation.
It is the best of times but also challenging times in the life sciences and pharmaceutical business, with unique opportunities and challenges in discovering, developing, launching, manufacturing, and marketing a promising drug for the global market. Advances in gene sequencing and editing, wearable technologies, and new scientific discoveries offer tremendous potential. It is clear that for market leadership, players in the pharmaceutical industry will need to strengthen several capabilities:
The Global Executive MBA Degree in Pharmaceutical Management programme is carefully curated to provide insight, planning, and execution skills to turbo-charge participants’ careers by focusing on all the issues above to drive growth.
The Amrut Mody School of Management offers a range of Management programmes, from Undergraduate to Doctoral degree as well as short term certificate programmes for practitioners. The School works closely with the industry to provide a balance between rigorous practice and strong conceptual education. It aligns with the University's vision with emphasis on interdisciplinary instruction. The School has adopted experiential learning pedagogies and introduced courses that use the Project Based Learning method.
To learn more please visit www.ahduni.edu.in/amsom
The Rady School of Management at the University of California San Diego is a professional school within one of the top-ranked institutions in the U.S. for higher education and research. Established in 2003, the Rady School of Management develops ethical and entrepreneurial leaders who make a positive impact in the world through innovation, collaboration and knowledge.
UC San Diego is recognised as one of the top universities in the world and is fortunate to yield a culturally diverse, international student body. The Rady School embraces cultural inclusion as essential to the fabric of the school. Diversity is fundamental to creativity, to innovation, to insight and especially to understanding, all of which contribute to the mosaic that makes Rady School so extraordinary.
To learn more please visit www.rady.ucsd.edu